Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors

Minying Cai, Udaya Kiran Marelli, Jennifer Bao, Johannes G. Beck, Florian Opperer, Florian Rechenmacher, Kaitlyn R. McLeod, Morgan R. Zingsheim, Lucas Doedens, Horst Kessler, Victor J Hruby

Research output: Contribution to journalArticle

10 Scopus citations


Human melanocortin receptors (hMCRs) have been challenging targets to develop ligands that are explicitly selective for each of their subtypes. To modulate the conformational preferences of the melanocortin ligands and improve the biofunctional agonist/antagonist activities and selectivities, we have applied a backbone N-methylation approach on Ac-Nle-c[Asp-His-d-Nal(2′)-Arg-Trp-Lys]-NH<inf>2</inf> (Ac-Nle<sup>4</sup>-c[Asp<sup>5</sup>,d-Nal(2′)<sup>7</sup>,Lys<sup>10</sup>]-NH<inf>2</inf>), a nonselective cyclic peptide antagonist at hMC3R and hMC4R and an agonist at hMC1R and hMC5R. Systematic N-methylated derivatives of Ac-Nle<sup>4</sup>-c[Asp<sup>5</sup>,d-Nal(2′)<sup>7</sup>,Lys<sup>10</sup>]-NH<inf>2</inf>, with all possible backbone N-methylation combinations, have been synthesized and examined for their binding and functional activities toward melanocortin receptor subtypes 1, 3, 4, and 5 (hMCRs). Several N-methylated analogues are selective and potent agonists or antagonists for hMC1R or hMC5R or have selective antagonist activity for hMC3R. The selective hMC1R ligands show strong binding for human melanoma cells. We have also discovered the first universal antagonist (compound 19) for all subtypes of hMCRs. (Figure Presented).

Original languageEnglish (US)
Pages (from-to)6359-6367
Number of pages9
JournalJournal of Medicinal Chemistry
Issue number16
StatePublished - Aug 27 2015


ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this